MESOBLAST LIMITED - Announcements

2.55%

$2.49

Market Cap $3.291B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company. The Company is engaged in developing... Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

MSB	FDA Confirms Path to Approval for CLBP		19/01/26	213.14KB	Share
MSB	Notification of cessation of securities - MSB		15/01/26	13.37KB	Share
MSB	Notification regarding unquoted securities - MSB		15/01/26	15.78KB	Share
MSB	Notification regarding unquoted securities - MSB		13/01/26	15.76KB	Share
MSB	Application for quotation of securities - MSB		13/01/26	17.37KB	Share
MSB	Appendix 3Y for Eric Rose		13/01/26	240.28KB	Share
MSB	Appendix 3Y for Lyn Cobley		12/01/26	252.36KB	Share
MSB	Ryoncil Sales for the Quarter Increase 60% to US$35.1M	PRICE SENSITIVE	09/01/26	214.95KB	Share
MSB	Appendix 3Y for Gregory George		06/01/26	258.38KB	Share
MSB	Notification of cessation of securities - MSB		06/01/26	12.76KB	Share
MSB	Mesoblast Announces Changes to Board of Director Roles		02/01/26	182.85KB	Share
MSB	Release of Shares from Voluntary Escrow		30/12/25	156.89KB	Share
MSB	Proposed issue of securities - MSB		30/12/25	16.62KB	Share
MSB	Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit	PRICE SENSITIVE	30/12/25	209.86KB	Share
MSB	Appendix 3Y for Gregory George		23/12/25	258.15KB	Share
MSB	Ceasing to be a substantial holder		19/12/25	937.38KB	Share
MSB	Notification regarding unquoted securities - MSB		17/12/25	17.69KB	Share
MSB	Becoming a substantial holder		17/12/25	1.43MB	Share
MSB	Warrant Prospectus Related to Convertible Note Agreements		16/12/25	696.05KB	Share
MSB	Study at ASH Concludes Remestemcel-L Superiority in SR-aGvHD		12/12/25	205.15KB	Share
MSB	Ceasing to be a substantial holder		10/12/25	316.83KB	Share
MSB	Becoming a substantial holder		09/12/25	1.44MB	Share
MSB	Mesoblast Participation at Piper Sandler Conference		04/12/25	183.04KB	Share
MSB	Ceasing to be a substantial holder		27/11/25	467.13KB	Share
MSB	Results of Meeting		25/11/25	194.81KB	Share
MSB	Ryoncil Revenue Growth Highlighted in AGM Trading Update	PRICE SENSITIVE	25/11/25	183.1KB	Share
MSB	CEO Presentation to 2025 Annual General Meeting	PRICE SENSITIVE	25/11/25	1.56MB	Share
MSB	Mesoblast Chair Message to 2025 AGM		25/11/25	184.37KB	Share
MSB	Mesoblast & BMT CTN to Initiate Adult aGvHD Trial of RYONCIL		21/11/25	219.73KB	Share
MSB	Appointment of Chief Financial Officer		17/11/25	185.67KB	Share
MSB	FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation		05/11/25	208.46KB	Share
MSB	Becoming a substantial holder		29/10/25	1.25MB	Share
MSB	Change of Director's Interest Notice		28/10/25	206.44KB	Share
MSB	Notification regarding unquoted securities - MSB		28/10/25	15.65KB	Share
MSB	Annual Report to Shareholders		27/10/25	3.48MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		27/10/25	474.64KB	Share
MSB	Appendix 4G and Corporate Governance Statement		27/10/25	470.17KB	Share
MSB	Ceasing to be a substantial holder		23/10/25	414.18KB	Share
MSB	Becoming a substantial holder		22/10/25	1.2MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/10/25	455.53KB	Share
MSB	Ceasing to be a substantial holder		15/10/25	892.87KB	Share
MSB	Notification of cessation of securities - MSB		14/10/25	13.35KB	Share
MSB	Notification regarding unquoted securities - MSB		14/10/25	15.74KB	Share
MSB	Application for quotation of securities - MSB		14/10/25	17.77KB	Share
MSB	Appendix 3Y for Eric Rose		14/10/25	236.44KB	Share
MSB	Becoming a substantial holder		14/10/25	2.5MB	Share
MSB	Ryoncil Revenues Increase 66% in Second Quarter Post Launch	PRICE SENSITIVE	07/10/25	201.89KB	Share
MSB	Ryoncil Receives CMS (Medicaid) J-Code for Reimbursement		03/10/25	204.45KB	Share
MSB	Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs		26/09/25	159.75KB	Share
MSB	Ceasing to be a substantial holder		22/09/25	539KB	Share
MSB	Becoming a substantial holder		16/09/25	470.67KB	Share
MSB	Becoming a substantial holder		16/09/25	149.97KB	Share
MSB	Ceasing to be a substantial holder		15/09/25	415.46KB	Share
MSB	Ryoncil Launch Highlighted at Global Healthcare Conferences		15/09/25	159.46KB	Share
MSB	Change of Director's Interest Notice		12/09/25	299.68KB	Share
MSB	Change in substantial holding		12/09/25	101.97KB	Share
MSB	Proposed issue of securities - MSB		04/09/25	16.86KB	Share
MSB	Mesoblast Option to Issue up to US$50m Convertible Notes	PRICE SENSITIVE	04/09/25	158.61KB	Share
MSB	Becoming a substantial holder		29/08/25	469.8KB	Share
MSB	MSB Annual Financial Results and Operational Update	PRICE SENSITIVE	29/08/25	411.86KB	Share
MSB	Annual Financial Results Presentation	PRICE SENSITIVE	29/08/25	2.08MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	29/08/25	2.69MB	Share
MSB	Mesoblast 2025 Full Year Financial Results Webcast		27/08/25	190.38KB	Share
MSB	Ceasing to be a substantial holder		25/08/25	584.98KB	Share
MSB	Becoming a substantial holder		29/07/25	806.3KB	Share
MSB	Ceasing to be a substantial holder		25/07/25	559.18KB	Share
MSB	Ceasing to be a substantial holder		25/07/25	1.58MB	Share
MSB	Becoming a substantial holder		23/07/25	2.04MB	Share
MSB	Ceasing to be a substantial holder		21/07/25	1.51MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	18/07/25	455.43KB	Share
MSB	Becoming a substantial holder		18/07/25	2.32MB	Share
MSB	Notification of cessation of securities - MSB		14/07/25	12.81KB	Share
MSB	Notification regarding unquoted securities - MSB		14/07/25	14.47KB	Share
MSB	Application for quotation of securities - MSB		14/07/25	17.77KB	Share
MSB	Notification regarding unquoted securities - MSB		14/07/25	15.93KB	Share
MSB	Ceasing to be a substantial holder		08/07/25	1.29MB	Share
MSB	Becoming a substantial holder		07/07/25	2.06MB	Share
MSB	Mesoblast and FDA Align on Key Items for Revascor BLA		01/07/25	184.33KB	Share
MSB	Ceasing to be a substantial holder		26/06/25	1.16MB	Share
MSB	Ceasing to be a substantial holder		18/06/25	243.32KB	Share
MSB	Becoming a substantial holder		17/06/25	1.88MB	Share
MSB	Ceasing to be a substantial holder		16/06/25	1.52MB	Share
MSB	Mesoblast Maintains Momentum with FDA		12/06/25	188.95KB	Share
MSB	Becoming a substantial holder		06/06/25	443.55KB	Share
MSB	Becoming a substantial holder		05/06/25	2.02MB	Share
MSB	Becoming a substantial holder		03/06/25	1006.62KB	Share
MSB	Ceasing to be a substantial holder		03/06/25	1.37MB	Share
MSB	FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval	PRICE SENSITIVE	15/05/25	173.92KB	Share
MSB	Becoming a substantial holder		14/05/25	1.85MB	Share
MSB	Ceasing to be a substantial holder		09/05/25	1.27MB	Share
MSB	Becoming a substantial holder		08/05/25	1.97MB	Share
MSB	Ceasing to be a substantial holder		07/05/25	241.08KB	Share
MSB	Becoming a substantial holder		02/05/25	328.2KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	440.59KB	Share
MSB	Initial Director's Interest Notice		29/04/25	230.8KB	Share
MSB	Director Appointment		29/04/25	182.59KB	Share
MSB	Appendix 3Y for Gregory George		24/04/25	256.27KB	Share
MSB	Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives		17/04/25	184.56KB	Share
MSB	Notification of cessation of securities - MSB		14/04/25	12.8KB	Share
MSB	Notification regarding unquoted securities - MSB		14/04/25	14.47KB	Share

MSB FDA Confirms Path to Approval for CLBP
19/01/26		213.14KB	Share
MSB Notification of cessation of securities - MSB
15/01/26		13.37KB	Share
MSB Notification regarding unquoted securities - MSB
15/01/26		15.78KB	Share
MSB Notification regarding unquoted securities - MSB
13/01/26		15.76KB	Share
MSB Application for quotation of securities - MSB
13/01/26		17.37KB	Share
MSB Appendix 3Y for Eric Rose
13/01/26		240.28KB	Share
MSB Appendix 3Y for Lyn Cobley
12/01/26		252.36KB	Share
MSB Ryoncil Sales for the Quarter Increase 60% to US$35.1M
09/01/26	PRICE SENSITIVE	214.95KB	Share
MSB Appendix 3Y for Gregory George
06/01/26		258.38KB	Share
MSB Notification of cessation of securities - MSB
06/01/26		12.76KB	Share
MSB Mesoblast Announces Changes to Board of Director Roles
02/01/26		182.85KB	Share
MSB Release of Shares from Voluntary Escrow
30/12/25		156.89KB	Share
MSB Proposed issue of securities - MSB
30/12/25		16.62KB	Share
MSB Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
30/12/25	PRICE SENSITIVE	209.86KB	Share
MSB Appendix 3Y for Gregory George
23/12/25		258.15KB	Share
MSB Ceasing to be a substantial holder
19/12/25		937.38KB	Share
MSB Notification regarding unquoted securities - MSB
17/12/25		17.69KB	Share
MSB Becoming a substantial holder
17/12/25		1.43MB	Share
MSB Warrant Prospectus Related to Convertible Note Agreements
16/12/25		696.05KB	Share
MSB Study at ASH Concludes Remestemcel-L Superiority in SR-aGvHD
12/12/25		205.15KB	Share
MSB Ceasing to be a substantial holder
10/12/25		316.83KB	Share
MSB Becoming a substantial holder
09/12/25		1.44MB	Share
MSB Mesoblast Participation at Piper Sandler Conference
04/12/25		183.04KB	Share
MSB Ceasing to be a substantial holder
27/11/25		467.13KB	Share
MSB Results of Meeting
25/11/25		194.81KB	Share
MSB Ryoncil Revenue Growth Highlighted in AGM Trading Update
25/11/25	PRICE SENSITIVE	183.1KB	Share
MSB CEO Presentation to 2025 Annual General Meeting
25/11/25	PRICE SENSITIVE	1.56MB	Share
MSB Mesoblast Chair Message to 2025 AGM
25/11/25		184.37KB	Share
MSB Mesoblast & BMT CTN to Initiate Adult aGvHD Trial of RYONCIL
21/11/25		219.73KB	Share
MSB Appointment of Chief Financial Officer
17/11/25		185.67KB	Share
MSB FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation
05/11/25		208.46KB	Share
MSB Becoming a substantial holder
29/10/25		1.25MB	Share
MSB Change of Director's Interest Notice
28/10/25		206.44KB	Share
MSB Notification regarding unquoted securities - MSB
28/10/25		15.65KB	Share
MSB Annual Report to Shareholders
27/10/25		3.48MB	Share
MSB Notice of Annual General Meeting and Proxy Form
27/10/25		474.64KB	Share
MSB Appendix 4G and Corporate Governance Statement
27/10/25		470.17KB	Share
MSB Ceasing to be a substantial holder
23/10/25		414.18KB	Share
MSB Becoming a substantial holder
22/10/25		1.2MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
20/10/25	PRICE SENSITIVE	455.53KB	Share
MSB Ceasing to be a substantial holder
15/10/25		892.87KB	Share
MSB Notification of cessation of securities - MSB
14/10/25		13.35KB	Share
MSB Notification regarding unquoted securities - MSB
14/10/25		15.74KB	Share
MSB Application for quotation of securities - MSB
14/10/25		17.77KB	Share
MSB Appendix 3Y for Eric Rose
14/10/25		236.44KB	Share
MSB Becoming a substantial holder
14/10/25		2.5MB	Share
MSB Ryoncil Revenues Increase 66% in Second Quarter Post Launch
07/10/25	PRICE SENSITIVE	201.89KB	Share
MSB Ryoncil Receives CMS (Medicaid) J-Code for Reimbursement
03/10/25		204.45KB	Share
MSB Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
26/09/25		159.75KB	Share
MSB Ceasing to be a substantial holder
22/09/25		539KB	Share
MSB Becoming a substantial holder
16/09/25		470.67KB	Share
MSB Becoming a substantial holder
16/09/25		149.97KB	Share
MSB Ceasing to be a substantial holder
15/09/25		415.46KB	Share
MSB Ryoncil Launch Highlighted at Global Healthcare Conferences
15/09/25		159.46KB	Share
MSB Change of Director's Interest Notice
12/09/25		299.68KB	Share
MSB Change in substantial holding
12/09/25		101.97KB	Share
MSB Proposed issue of securities - MSB
04/09/25		16.86KB	Share
MSB Mesoblast Option to Issue up to US$50m Convertible Notes
04/09/25	PRICE SENSITIVE	158.61KB	Share
MSB Becoming a substantial holder
29/08/25		469.8KB	Share
MSB MSB Annual Financial Results and Operational Update
29/08/25	PRICE SENSITIVE	411.86KB	Share
MSB Annual Financial Results Presentation
29/08/25	PRICE SENSITIVE	2.08MB	Share
MSB Preliminary Final Report including Appendix 4E
29/08/25	PRICE SENSITIVE	2.69MB	Share
MSB Mesoblast 2025 Full Year Financial Results Webcast
27/08/25		190.38KB	Share
MSB Ceasing to be a substantial holder
25/08/25		584.98KB	Share
MSB Becoming a substantial holder
29/07/25		806.3KB	Share
MSB Ceasing to be a substantial holder
25/07/25		559.18KB	Share
MSB Ceasing to be a substantial holder
25/07/25		1.58MB	Share
MSB Becoming a substantial holder
23/07/25		2.04MB	Share
MSB Ceasing to be a substantial holder
21/07/25		1.51MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
18/07/25	PRICE SENSITIVE	455.43KB	Share
MSB Becoming a substantial holder
18/07/25		2.32MB	Share
MSB Notification of cessation of securities - MSB
14/07/25		12.81KB	Share
MSB Notification regarding unquoted securities - MSB
14/07/25		14.47KB	Share
MSB Application for quotation of securities - MSB
14/07/25		17.77KB	Share
MSB Notification regarding unquoted securities - MSB
14/07/25		15.93KB	Share
MSB Ceasing to be a substantial holder
08/07/25		1.29MB	Share
MSB Becoming a substantial holder
07/07/25		2.06MB	Share
MSB Mesoblast and FDA Align on Key Items for Revascor BLA
01/07/25		184.33KB	Share
MSB Ceasing to be a substantial holder
26/06/25		1.16MB	Share
MSB Ceasing to be a substantial holder
18/06/25		243.32KB	Share
MSB Becoming a substantial holder
17/06/25		1.88MB	Share
MSB Ceasing to be a substantial holder
16/06/25		1.52MB	Share
MSB Mesoblast Maintains Momentum with FDA
12/06/25		188.95KB	Share
MSB Becoming a substantial holder
06/06/25		443.55KB	Share
MSB Becoming a substantial holder
05/06/25		2.02MB	Share
MSB Becoming a substantial holder
03/06/25		1006.62KB	Share
MSB Ceasing to be a substantial holder
03/06/25		1.37MB	Share
MSB FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
15/05/25	PRICE SENSITIVE	173.92KB	Share
MSB Becoming a substantial holder
14/05/25		1.85MB	Share
MSB Ceasing to be a substantial holder
09/05/25		1.27MB	Share
MSB Becoming a substantial holder
08/05/25		1.97MB	Share
MSB Ceasing to be a substantial holder
07/05/25		241.08KB	Share
MSB Becoming a substantial holder
02/05/25		328.2KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	440.59KB	Share
MSB Initial Director's Interest Notice
29/04/25		230.8KB	Share
MSB Director Appointment
29/04/25		182.59KB	Share
MSB Appendix 3Y for Gregory George
24/04/25		256.27KB	Share
MSB Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives
17/04/25		184.56KB	Share
MSB Notification of cessation of securities - MSB
14/04/25		12.8KB	Share
MSB Notification regarding unquoted securities - MSB
14/04/25		14.47KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.49		Change -0.065(2.55%)		Mkt cap ! $3.291B

Open	High	Low	Volume
$2.49	$2.51	$2.47	1.161M

Buyers (Bids)

Vol.	Price($)
137597	$2.48

Sellers (Offers)

Price($)	Vol.
$2.49	3027

Last trade - 11.07am 21/01/2026 (20 minute delay)

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories